Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

06.03.2018 | Epidemiology

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer

verfasst von: Marzana Chowdhury, David Euhus, Maureen O’Donnell, Tracy Onega, Pankaj K. Choudhary, Swati Biswas

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Increased mammographic breast density is a significant risk factor for breast cancer. It is not clear if it is also a risk factor for the development of contralateral breast cancer.

Methods

The data were obtained from Breast Cancer Surveillance Consortium and included women diagnosed with invasive breast cancer or ductal carcinoma in situ between ages 18 and 88 and years 1995 and 2009. Each case of contralateral breast cancer was matched with three controls based on year of first breast cancer diagnosis, race, and length of follow-up. A total of 847 cases and 2541 controls were included. The risk factors included in the study were mammographic breast density, age of first breast cancer diagnosis, family history of breast cancer, anti-estrogen treatment, hormone replacement therapy, menopausal status, and estrogen receptor status, all from the time of first breast cancer diagnosis. Both univariate analysis and multivariate conditional logistic regression analysis were performed.

Results

In the final multivariate model, breast density, family history of breast cancer, and anti-estrogen treatment remained significant with p values less than 0.01. Increasing breast density had a dose-dependent effect on the risk of contralateral breast cancer. Relative to ‘almost entirely fat’ category of breast density, the adjusted odds ratios (and p values) in the multivariate analysis for ‘scattered density,’ ‘heterogeneously dense,’ and ‘extremely dense’ categories were 1.65 (0.036), 2.10 (0.002), and 2.32 (0.001), respectively.

Conclusion

Breast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Literatur
1.
Zurück zum Zitat Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed
2.
Zurück zum Zitat Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed
3.
Zurück zum Zitat King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed
4.
Zurück zum Zitat Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the national cancer data base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the national cancer data base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed
5.
Zurück zum Zitat Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589CrossRef Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589CrossRef
7.
Zurück zum Zitat Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: Impact on survival after unilateral breast cancer is stage-dependent. ASCO Breast Cancer Symposium Abstract vol 69 Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: Impact on survival after unilateral breast cancer is stage-dependent. ASCO Breast Cancer Symposium Abstract vol 69
9.
Zurück zum Zitat Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40CrossRefPubMed Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40CrossRefPubMed
10.
Zurück zum Zitat Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed
13.
Zurück zum Zitat Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed
14.
Zurück zum Zitat Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed
15.
Zurück zum Zitat Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed
17.
Zurück zum Zitat Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef
18.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
19.
Zurück zum Zitat Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed
20.
Zurück zum Zitat Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861PubMed Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861PubMed
21.
Zurück zum Zitat Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed
22.
Zurück zum Zitat Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed
25.
Zurück zum Zitat Habel LA, Capra AM, Achacoso NS et al (2010) Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 19:2488–2495CrossRefPubMed Habel LA, Capra AM, Achacoso NS et al (2010) Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 19:2488–2495CrossRefPubMed
26.
Zurück zum Zitat Hwang ES, Miglioretti DL, Ballard-Barbash R et al (2007) Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2587–2593CrossRefPubMed Hwang ES, Miglioretti DL, Ballard-Barbash R et al (2007) Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2587–2593CrossRefPubMed
27.
Zurück zum Zitat Raghavendra A, Sinha AK, Le-Petross HT et al (2017) Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123:1935–1940CrossRefPubMedPubMedCentral Raghavendra A, Sinha AK, Le-Petross HT et al (2017) Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123:1935–1940CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. International Agency for Research on Cancer, Lyon Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. International Agency for Research on Cancer, Lyon
32.
Zurück zum Zitat Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd ed. Wiley, hoboken Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd ed. Wiley, hoboken
33.
Zurück zum Zitat Development Core Team R (2016) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna Development Core Team R (2016) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna
35.
Zurück zum Zitat Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, BerlinCrossRef Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, BerlinCrossRef
36.
Zurück zum Zitat Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed
Metadaten
Titel
Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer
verfasst von
Marzana Chowdhury
David Euhus
Maureen O’Donnell
Tracy Onega
Pankaj K. Choudhary
Swati Biswas
Publikationsdatum
06.03.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4736-8

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.